Enrique Poradosu

Chief Scientific & Business OfficeratNuvectis Pharma· In proxies 2022–2025

Pay in FY2025-13% from the year before · Nuvectis Pharma stock +39.6% the same year

Enrique Poradosu was paid $1.6M in FY2025 (Dec), down 13%. Nuvectis Pharma stock rose 39.6% that year.

Pay$100 in the stock at the end of FY22 → $101

Pay is from the Summary Compensation Table of each Nuvectis Pharma proxy. The stock line is the value of $100 put in the stock at the start, from the price change of each fiscal year. Dividends are not in it.

Experience

NVCT
Nuvectis PharmaPublic company · 4 yr
- Chief Scientific & Business Officer2022 – Present · 4 yrStock in role +465%

Roles come from the proxy statements of each company.

Activity

Pay
Nuvectis Pharma Division head pay fell 13% to $1.6M. The stock rose 40% in FY2025 (Dec).
DEF 14AApr 27, 2026
Pay
Nuvectis Pharma Division head pay rose 16% to $1.8M. The stock fell 35% in FY2024 (Dec).
DEF 14AApr 28, 2025
Pay
Nuvectis Pharma Division head pay rose 61% to $1.6M. The stock rose 11% in FY2023 (Dec).
DEF 14AApr 29, 2024

For the press:Download CSV Download PNG How to use our data

Two people shown as one, or a wrong number?